Cannabinoids have been associated with improved outcomes in non alcoholic fatty liver disease

August 30, 2019 0
liver2.jpg

The increased development of obesity and excess weight can lead to non-alcoholic fatty liver diseases. Recent findings suggest that cannabis use has a protective effect on weight gain and associated metabolic changes in  patients with psychosis.

According to a three year longitudinal study published in 2019, cannabis use can have a protective effect against liver steatosis.

390 patients were examined at two points in time.  Firstly, at the start of the study, and secondly, after 3 years of initiating antipsychotic treatment. Anthropometric measurements and liver, lipid, and glycemic parameters were obtained at both points in time. Patients were treated at the Department of Psychiatry of the University Hospital de Valdecilla in Santander, Spain. 

During the second examination, cannabis users significantly had lower FLI (Fatty Liver Index) values than non-users.

In addition, cannabis users met the criteria for liver steatosis less frequently than non-users. Patients who consistently used cannabis after 3 years of use represented the smallest increase in FLI over time. 

Source:Cannabis-Med


Leave a Reply

Your email address will not be published. Required fields are marked *


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

IberCanPharma LDA
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain